Kwality Pharmaceuticals Limited

Valuation elevated: PE 53 leaves minimal buffer for earnings misses — verify if growth pace justifies this multiple.

Margin sustainability uncertain: OPM improved from 21.68% to 24.7% — verify if this is from durable improvements (scale, mix) or temporary tailwinds.

Weak institutional backing: FII at 3.13%, DII at 0.56% — verify why professional investors have limited exposure despite growth narrative.

Stock volatility high: 52w range ₹838–₹3,436 (4.1x) and 213% 1y return — verify if price reflects fundamentals or speculative momentum.

Revenue grew from ₹80 Cr (Jun 2024) to ₹157 Cr (Mar 2026), a 45% CAGR — verify which products, segments, or markets are driving this growth.

Net profit increased 3x (₹8.37 Cr to ₹25.29 Cr) in same period, faster than revenue growth — verify if from margin expansion, mix, or pricing.

Operating margins expanded from 21.68% to 24.7%, suggesting operational improvements — verify if sustainable as company scales.

Market confidence strong: 213% 1y return indicates investor optimism — verify if medium-term growth visibility supports valuation or if speculative.